How Has The Neonatal Respiratory Distress Syndrome Treatment Market Size Evolved In Recent Years?
The neonatal respiratory distress syndrome treatment market has seen considerable growth due to a variety of factors.
• The market for treating neonatal respiratory distress syndrome has seen a considerable increase in size in the past few years. The market is expected to rise from a value of $0.96 billion in 2024 to a total of $1.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.3%.
Factors contributing to this growth within the historical timeframe include rising alveolar-capillary permeability, increased use of mechanical ventilation, amplified awareness regarding the significance of neonatal care among healthcare providers and parents, and a surge in investments in the healthcare sector.
What are the Market Size and Expected Growth Rates for the Neonatal Respiratory Distress Syndrome Treatment Market?
The neonatal respiratory distress syndrome treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for neonatal respiratory distress syndrome treatment is projected to experience substantial growth in the coming years, expanding to $1.41 billion by 2029 at an 8.0% compound annual growth rate.
The expected growth during the forecast period is due to factors such as growing inclination towards accessories and consumables, an upsurge in NICU admissions, escalating demand for customised medicine, rising instances of premature birth, and an increase in research and development activities. Noteworthy developments during the estimated period include the automation of neonatal intensive care units (NICUs), incorporation of artificial intelligence (AI), technological advancements in neonatal care, surfactant therapy innovation, and progressive ventilator technologies.
What Are the Critical Driver Fuelling the Neonatal Respiratory Distress Syndrome Treatment Market's Growth?
The surge in cases of premature births is anticipated to boost the advancement of the neonatal respiratory distress syndrome treatment market. A premature, or preterm birth, occurs when a child is born before the 37-week gestation period, with more severe health threats faced by those born before 32 weeks because a conventional pregnancy is closer to 40 weeks long. An increase in premature births can be attributed to factors such as late maternal age, multiple pregnancies, medical conditions, lifestyle decisions, fertility treatments, infections, and surrounding environmental influences. Neonatal respiratory distress syndrome (NRDS), which often affects premature infants due to their lung development and insufficient surfactant production, necessitates treatment. Such treatment improves lung functionality, maintains steady breathing, and lowers the chance of respiratory failure in premature infants. For example, Tommy's, a charity organization based in the UK, reported that the fraction of live premature births in England and Wales was 7.9% in 2022, rising from 7.5% in 2021. This rise illustrates the second successive year of premature birth increases. Over 53,000 premature births happened in 2022. Consequently, the escalation of premature births is fueling the growth of the neonatal respiratory distress syndrome treatment market.
What Are The Key Segments Within The Global Neonatal Respiratory Distress Syndrome Treatment Market?
The neonatal respiratory distress syndrome treatment market covered in this report is segmented –
1) By Therapy: Oxygen Therapy, Surfactant Therapy
2) By Route Of Administration: Parenteral, Inhalation, Other Routes Of Administration
3) By End User: Hospitals, Sub-Acute Facilities, Home Care, Retail Pharmacies
Subsegments:
1) By Oxygen Therapy: Conventional Oxygen Therapy, High-Flow Nasal Cannula (HFNC) Oxygen Therapy, Continuous Positive Airway Pressure (CPAP) Oxygen Therapy, Invasive Mechanical Ventilation With Oxygen Therapy
2) By Surfactant Therapy: Natural Surfactants, Synthetic Surfactants, Combined Surfactant Therapy (Natural + Synthetic), Prophylactic Surfactant Therapy, Rescue Surfactant Therapy
Pre-Book The Neonatal Respiratory Distress Syndrome Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Neonatal Respiratory Distress Syndrome Treatment Market?
Leading corporations in the neonatal respiratory distress syndrome treatment market are shifting their focus towards the creation of sophisticated technologies like nitric oxide generators. These technologies are intended to improve oxygenation, reduce respiratory issues, and provide gentler treatment options for newborns suffering from hypoxic respiratory failure. Nitric oxide generators are medical tools used to produce and administer nitric oxide gas, a common treatment for respiratory conditions intended to increase oxygenation and alleviate pulmonary hypertension, particularly in neonates and severely ill patients. For example, in June 2022, Beyond Air Inc., a medical device and biopharmaceutical firm based in the US, received FDA approval for their product, LungFit PH. This state-of-the-art nitric oxide generator is intended to help term and near-term newborns suffering from hypoxic respiratory failure, including persistent pulmonary hypertension of the newborn (PPHN). The device uses Beyond Air's proprietary Ionizer technology to produce nitric oxide from the surrounding air on demand, ensuring an infinite supply without any concerns about dosage or flow. It also uses a low-powered compressor to ionize nitrogen and oxygen, thus reducing nitrogen dioxide (NO2) creation which is then efficiently filtered through a smart filter.
Who Are the Key Players in the Neonatal Respiratory Distress Syndrome Treatment Market?
Major companies operating in the neonatal respiratory distress syndrome treatment market are include:
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Abbott Laboratories
• Medtronic Plc
• Medline Industries
• Becton Dickinson
• Stryker Corporation
• GE Healthcare
• Koninklijke Philips NV
• ResMed Inc.
• Drägerwerk AG & Co. KGaA
• Chiesi Farmaceutici
• ICU Medical Inc.
• Fisher & Paykel Healthcare
• Vyaire Medical
• Laerdal Medical
• Hamilton Medical
• Inspiration Healthcare
• Ventec Life Systems
• Neotech Products
• Aerogen Pharma Corp.
• Windtree Therapeutics Inc.
• Discovery Laboratories Inc.
• Lyomark Pharma GmbH
What are the Regional Insights into the Neonatal Respiratory Distress Syndrome Treatment Market?
North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neonatal respiratory distress syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
